CDTX Valuation

Cidara Therapeutics Inc

Add to Watchlist

Advanced Chart

61.850

-0.97(-1.544%)1D

Overview
Forecast
Valuation
Earnings

CDTX Relative Valuation

CDTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CDTX is overvalued; if below, it's undervalued.

Historical Valuation

Cidara Therapeutics Inc (CDTX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -2.95. The fair price of Cidara Therapeutics Inc (CDTX) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：61.85

Fair

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

5.41

P/B

Median3y

0.57

Median5y

1.24

-13.38

FCF Yield

Median3y

-61.26

Median5y

-57.05

Competitors Valuation Multiple

The average P/S ratio for CDTX's competitors is 159.36, providing a benchmark for relative valuation. Cidara Therapeutics Inc Corp (CDTX) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of -100.00%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

CDTX.O

Cidara Therapeutics Inc

Loss

Average P/S: 159.36

-100.00%